Abstract
I wish to provide a brief comment on the impressive randomised trial by Michael Weber and colleagues,1 which shows that the endothelin-receptor antagonist darusentan provides additional reductions in blood pressure in patients who have not attained their treatment goals with three or more antihypertensive drugs.
| Original language | English |
|---|---|
| Pages (from-to) | 636-636 |
| Number of pages | 1 |
| Journal | The Lancet |
| Volume | 375 |
| Issue number | 9715 |
| DOIs | |
| Publication status | Published - 22 Feb 2010 |
| Externally published | Yes |